Post

New research · Otolaryngology (ENT)
The Lancet. Respiratory medicine · 1d
Randomized trialThe Lancet. Respiratory medicine · 2025

Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.

Eugenio De Corso, G Walter Canonica, Enrico Heffler … Peter W Hellings
Read paper
Otolaryngology (ENT)Randomized trial

Dupilumab significantly improved nasal polyp scores more than omalizumab in chronic rhinosinusitis.

Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.

Eugenio De Corso et al. · The Lancet. Respiratory medicine · 2025
Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation.

Purpose

In EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), the first head-to-head trial in respiratory biologics, we aimed to compare the efficacy and safety of dupilumab and omalizumab in patients with severe CRSwNP who had mild, moderate, or severe asthma.

Methods

And investigators were masked to the study drugs.

n = 819 individuals
Results
dupilumab improved nasal polyp severity more than omalizumab
n = 819 individuals
More results

Improvements were significantly greater with dupilumab than omalizumab for all primary and secondary efficacy endpoints at week 24.

More results

115 (64%) of 179 participants in the dupilumab group and 116 (67%) of 173 participants in the omalizumab group reported treatment-emergent adverse events, the most common of which were nasopharyngitis, accidental overdose, headache, upper respiratory tract infection, and cough.

There were no deaths in the study.

“
Conclusion · 1 of 2

Dupilumab was superior to omalizumab in patients with severe CRSwNP and coexisting asthma.

Conclusion · 2 of 2

These findings support the efficacy of dupilumab in patients with type 2 respiratory diseases versus an active biologic comparator, the known safety profiles of dupilumab and omalizumab, and could enable better treatment targeting for patients with CRSwNP and asthma in clinical practice.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
65.4% reduction
fewer patients needed surgery to stop bleeding after tonsil removal
Cross-sectional
21.1%
fear of illness was the most common workplace challenge for ear, nose, and throat staff
Guideline
“This is the first Brazilian consensus on glottoplasty for transgender women, providing structured clinical guidance for indication, technical execution, and follow-up. Higher-level evidence is needed to strengthen future recommendations.”
Cohort Study
aHR: 0.46
Otolaryngology consultation is associated with a 54% lower hazard of diagnosis after 3 months.
Cohort Study
51.2%
over half of children with a breathing tube experienced problems later on
Observational
β = 0.075
worse emotional well-being was associated with higher self-stigma
Animal / Preclinical
0%
no deep learning studies were tested with patients in real healthcare settings